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background: Cardiac myosin binding protein-C (MyBPC3) releases its inhibition on cross-bridge cycling when phosphorylated. Thus, we hypothesize 
that phosphorylated MyBPC3 enhances relaxation to mediate diastolic function as underlying mechanism and potential treatment for heart failure 
with preserved ejection fraction (HFpEF).
Methods: We compare mouse models of phosphorylation deficient MyBPC3(t3SA), phosphorylation mimetic MyBPC3(t3SD) and WT-control 
MyBPC3(tWT) by echocardiography, intra-cardiac pressure volume measurements and simultaneous force/intracellular calcium [Ca2+]i 
measurements on intact papillary muscles.
results: t3SA hearts show diastolic dysfunction with low Ea and reduced Ea/Sa ratio but t3SD hearts exhibit enhancement of both. Ea and Sa are 
peak myocardial relaxation and contraction tissue Doppler velocities respectively. t3SD hearts show smallest pressure relaxation rate constant Tau-
Glantz and smallest stiffness constant equating enhanced lusitropy. t3SA papillary muscles exhibit slowed force decay rate constant kForce signifying 
impaired lusitropy . Increasing pacing frequency (1-2.5 Hz) accelerated relaxation in tWT and t3SD muscles but poorly in t3SA. All models show 
similar [Ca2+]i decay rate constant kCa suggesting phosphorylated MyBPC3 enhances lusitropy via modulation of cross-bridge cycling independent 
of calcium handling.
conclusion: Phosphorylated MyBPC3 enhances lusitropy, constituting a potential mechanism of treatment for HFpEF.
Echocardiography MyBPC3(tWT), n:16 MYBCPC3(t3SA), n:14 MYBCPC3(t3SD), n:14
Ea (mm/s) 27.82±1.25# 16.45±1.34*,# 38.28±1.65*
Ea/Sa 1.27±0.07# 0.99±0.05*,# 1.59±0.09*
Iso-volumetric
Relaxation time (ms)
20.5±0.7 33.8±1.2*,# 18.7±1.0
Pressure-Volume
Tau Glantz (ms) 20.16±2.85#, n:6 26.13±1.27*,#, n:10 13.05±0.99*, n:10
Stiffness (mmHg/µL) 0.07±0.02#, n:5 0.13±0.02*,#, n:8 0.01±0.00*α, n:7
Intact Papillary Muscles n:8 n:6 n:9
KForce (1/s) at 1 Hz 9.37±0.92 9.51±0.67 10.96±1.43
KForce (1/s) at 2.5 Hz 19.33±1.24∞ 13.87±0.77*# 22.21±1.03∞
kCa (1/s) at 1 Hz 3.89±0.28 3.60±0.11 3.75±0.07
kCa (1/s) at 2.5 Hz 7.92±0.48∞ 7.39±0.49 ∞ 8.12±0.33∞
*p<0.05 vs. MyBPC3(tWT), #p<0.05 vs. MyBPC3(t3SD), ∞p<0.05 vs. 1.0Hz, Mean ± SE
